CMN Weekly (17 January 2025) - Your Weekly CRISPR...
CMN Weekly
Jan. 17, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
HuidaGene Therapeutics
Company Type: Therapeutics
Main focus: Development of novel genomic medicines for diverse diseases
Company stage: Clinical
Diseases: Ophthalmology, neurology, neuro-myology, otology and neurology
Genome-editing tool: CRISPR-Cas12 and CRISPR-Cas13
Funding stage: Series C
Location: Shangay, China
Website: https://www.huidagene.com/
Pipeline:https://www.huidagene.com/program-pipeline/pipeline
Partners:
HuidaGene is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing gene-editing tools and gene therapies develop novel genetic medicines. Based in Shanghai and New Jersey, HuidaGene is addressing patients’ needs globally with various therapeutic programmes spanning ophthalmology, neurology, neuro-myology, otology and neurology.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
Neovascular Age-Related Macular Degeneration, nAMD, (NCT06623279)
Sponsors:
HuidaGene Therapeutics Co., Ltd.
Sponsors:
HuidaGene Therapeutics Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Neovascular Age-related Macular Degeneration, nAMD, (NCT06031727)
Sponsors:
HuidaGene Therapeutics Co., Ltd.
Sponsors:
HuidaGene Therapeutics Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
